Advicenne develops paediatric-friendly therapeutics focused on orphan renal and neurological diseases, with lead programs in nephrology and neurology. Its lead product, ADV7103, is in a pivotal Phase III trial in Europe targeting a renal tubulopathy (an orphan indication). The company expects to announce Phase III results for ADV7103 during summer 2017 and is pursuing a second renal indication in Europe. Advicenne also plans the registration of ADV6209, a paediatric anaesthesiology product it outlicensed to Primex Pharmaceuticals in 2016. The company is led by CEO Dr. Luc-André Granier. Recently it closed a €16M financing (approx. $17.2M) to advance its late-stage pipeline. Advicenna Pharma is a biopharmaceutical company focused on developing and marketing paediatric products targeting neurological diseases and nephrological disorders. The company is based in Castries, France and was founded in 2007. It is led by Luc André Granier and Mme Caroline Roussel-Maupetit. Advicenna intends to use the newly raised funds to advance its programs clinically and to enroll its first products. The articles note the company previously raised its first round in its founding year. The current financing increases resources available to support clinical development and regulatory progress.

Total raised

$24M

Funding rounds

2

Latest round

Equity

Latest activity

Mar 2017